HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
Copyright policy )HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has been validated in vitro and in several murine models of chronic kidney diseases (CKD).
- United States Department of Veterans Affairs United States
- Icahn School of Medicine at Mount Sinai United States
Inflammation, kidney, Physiology, fibrosis, HIPK2, Kidney, Fibrosis, Signaling Pathways, signaling pathways, inflammation, QP1-981
Inflammation, kidney, Physiology, fibrosis, HIPK2, Kidney, Fibrosis, Signaling Pathways, signaling pathways, inflammation, QP1-981
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).25 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!